BDI-1-MT治疗膀胱癌及预防其术后复发的临床观察

CLINICAL OBSERVATION OF BDI-1-MT FOR THE TREATMENT OF BLADDER CARCINOMA AND PREVENTION OF CURRENCE AFTER SURGERY

目的 通过临床应用膀胱腔内灌注抗人膀胱癌免疫毒素 (BDI- 1-MT) ,观察治疗膀胱癌和预防膀胱癌术后复发的效果及毒副反应。方法 对 18例术后和 5例未手术的膀胱癌病人 ,膀胱腔内灌注BDI- 1-MT 1个疗程以上 ,观察疗效、复发情况及毒副反应。结果 术后 18例随访 6～ 2 0个月未见复发 ,未手术 5例随访 6～ 2 1个月 ,其中 3例显效 ,2例有效。所有病例均无明显毒副反应。结论 膀胱腔内灌注BDI- 1-MT治疗膀胱癌和预防膀胱癌术后复发有良好效果 ,是一种值得推广的新方法。

Objective To observe the clinical efficacy of BDI-1-MT for the treatment of bladder carcinoma and the role of BDI-1-MT for the prevention of currence and the side effects into to the bladders after surgery. Method 23 patients with bladder carcinoma were treated with the instillation of BDI-1-MT into the bladder cavity for more than one course. 18 patients were after surgery and 5 patients were before surgery. The clinical efficacy, currence and side effects were evaluated. Results All 18 patients with surgery were followed up for 6 to 20 months and no one showed recurrence. The 5 patients without surgery were followed up for 6 to 21 months, three patients have been achieved in complete tumor regression and the rest two showed partial effectiveness. All the patients with the application of BDI-1-MT showed no obvious side effects. Conclusion The intravesical instillation of BDI-1-MT has better efficacy for the treatment of bladder carcinoma. This method can also prevent the currence of bladder carcinoma after surgery. The application of BDI-1-MT should be well worth spread.